A Research Pipeline to Deliver First-in-Class Therapies to the Clinic

We continue to investigate how our innovative approaches to medicine may serve the needs of patients with cancer. We are engaged in continued research to generate new oncology drug candidates using our proprietary assets and expertise in telomerase and nucleic acid chemistry. Our oncology discovery research includes:

  • Using our proprietary nucleic acid platform to develop drug candidates against oncology targets
  • Finding additional ways to target telomerase
  • Investigating the use of receptor-targeting peptides to transport telomerase inhibitors into the brain

In addition, we continue to investigate other aspects of telomere biology, including telomerase activation.

Close Video
Close Window
Close
Form content here please :)